Sugi Predict

Sugi Predict / Compounds / SCHEMBL270422

SCHEMBL270422

SCHEMBL270422

Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1N

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK1 P23458 6/20 0.63
▸ BRD4 O60885 5/20 0.63
▸ JAK2 O60674 5/20 0.63
▸ JAK3 P52333 5/20 0.63
▸ HDAC1 Q13547 3/20 0.63
▸ TYK2 P29597 3/20 0.63
▸ RET P07949 2/20 0.63
▸ FLT3 P36888 2/20 0.63
▸ HDAC8 Q9BY41 1/20 0.63
▸ HDAC6 Q9UBN7 1/20 0.63
▸ AXL P30530 6/20 0.60
▸ BACE1 P56817 6/20 0.57
▸ BRDT Q58F21 2/20 0.57
▸ BRD2 P25440 1/20 0.57
▸ BRD3 Q15059 1/20 0.57
▸ BRAF P15056 2/20 0.56
▸ SRC P12931 5/20 0.56
▸ ABL1 P00519 2/20 0.55
▸ EGFR P00533 2/20 0.55
▸ LCK P06239 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3968637 0.86 JAK1 (0.69) JAK1BRD4JAK2JAK3HDAC1
SCHEMBL3963144 0.86 AXL (0.68) JAK1BRD4JAK2JAK3HDAC1
SCHEMBL12278161 0.85 JAK1 (0.71) JAK1BRD4JAK2JAK3HDAC1
SCHEMBL28677225 0.85 BRD4 (0.73) JAK1BRD4JAK2JAK3HDAC1
SCHEMBL17915915 0.84 BRAF (0.56) JAK1BRD4JAK2JAK3HDAC1
SCHEMBL269991 0.84 JAK1 (0.75) JAK1BRD4JAK2JAK3HDAC1
SCHEMBL265892 0.84 CDK1 (0.59) JAK1BRD4JAK2JAK3HDAC1
SCHEMBL265437 0.84 JAK3 (0.74) JAK1BRD4JAK2JAK3HDAC1
SCHEMBL270390 0.84 BACE1 (0.56) JAK1BRD4JAK2JAK3HDAC1
Hydrochloric Acid SCHEMBL265421 0.84 JAK1 (0.74) JAK1BRD4JAK2JAK3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10730860-B2 Diaminopyrimidine benzenesulfone derivatives and uses thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-08-04 — — US disclosed
US-20190135790-A1 DIAMINOPYRIMIDINE BENZENESULFONE DERIVATIVES AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2019-05-09 — — US disclosed
US-10150756-B2 Diaminopyrimidine benzenesulfone derivatives and uses thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2018-12-11 — — US disclosed
EP-3099677-A1 DIAMINOPYRIMIDINE BENZENESULFONE DERIVATIVES AND USES THEREOF Dana-Farber Cancer Institute, Inc. (US) 2016-12-07 — — EP disclosed
US-20160332993-A1 DIAMINOPYRIMIDINE BENZENESULFONE DERIVATIVES AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2016-11-17 — — US disclosed
EP-1951684-B1 BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES TARGEGEN INC (US) 2016-07-13 — — EP disclosed
WO-2015117053-A1 DIAMINOPYRIMIDINE BENZENESULFONE DERIVATIVES AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2015-08-06 — — WO disclosed
US-8604042-B2 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2013-12-10 — — US disclosed
US-8138199-B2 Use of bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2012-03-20 — — US disclosed
US-8138199-B2 Use of bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2012-03-20 — — US disclosed
US-20090275582-A1 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases IMPACT BIOMEDICINES, INC. 2009-11-05 — — US disclosed
US-7528143-B2 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2009-05-05 — — US disclosed
US-7528143-B2 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2009-05-05 — — US disclosed
US-7528143-B2 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2009-05-05 — — US disclosed
US-20070259904-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-11-08 — — US disclosed
US-20070259904-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-11-08 — — US disclosed
US-20070259904-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-11-08 — — US disclosed
US-20070191405-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-08-16 — — US disclosed
US-20070191405-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-08-16 — — US disclosed
US-20070191405-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-08-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160332993-A1 DIAMINOPYRIMIDINE BENZENESULFONE DERIVATIVES AND USES THEREOF BRDT, BRD4, BRPF3 JAK1 2536/4885BRD4 2/4885JAK2 806/4885
US-20070191405-A1 Bi-aryl meta-pyrimidine inhibitors of kinases JAK2, TYK2, JAK3 JAK1 4/4885BRD4 142/4885JAK2 1/4885
US-10150756-B2 Diaminopyrimidine benzenesulfone derivatives and uses thereof BRDT, BRD4, BRPF3 JAK1 2536/4885BRD4 2/4885JAK2 806/4885
US-20070259904-A1 Bi-aryl meta-pyrimidine inhibitors of kinases JAK2, TYK2, JAK3 JAK1 4/4885BRD4 142/4885JAK2 1/4885
US-20090275582-A1 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases JAK2, TYK2, JAK3 JAK1 4/4885BRD4 142/4885JAK2 1/4885
US-20190135790-A1 DIAMINOPYRIMIDINE BENZENESULFONE DERIVATIVES AND USES THEREOF BRDT, BRD4, BRPF3 JAK1 2536/4885BRD4 2/4885JAK2 806/4885
US-10730860-B2 Diaminopyrimidine benzenesulfone derivatives and uses thereof BRDT, BRD4, BRPF3 JAK1 2536/4885BRD4 2/4885JAK2 806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.